±Ý¿¬ ¾à¹°Ä¡·áÀÇ ÃֽŠÁö°ß
Recent Updates of Medication for Smoking Cessation
´ëÇѱݿ¬ÇÐȸÁö 2014³â 5±Ç 2È£ p.70 ~ p.75
Á¤¼¼¿µ(Jung Se-Young) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ °¡Á¤ÀÇÇб³½Ç
À̱âÇå(Lee Ki-Heon) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ °¡Á¤ÀÇÇб³½Ç
±è»ç¶ó(Kim Sa-Rah) - ¼¿ï´ëÇб³ ÀÇ°ú´ëÇÐ °¡Á¤ÀÇÇб³½Ç
Abstract
This year marked the 50th anniversary of the release of Surgeon Generals report on the adverse effect of smoking. Unfortunately, smoking is still one of the major causes of premature deaths worldwide. In the US alone, tobacco has caused over 20 million deaths over the last 50 years, a number equivalent to the number of deaths resulting from a war. Consequently, the war on tobacco use has come a long way since then. Several countries have taken measures to restrict the consumption of tobacco usage. In the States, Europe and Korea, medications such as varenicline, bupropion, nortriptyline, and nicotine replacement therapies have been widely used for treatment. Nicotine receptor partial agonists, anxiolytics, clonidine, lobeline, mekamylamine, nicobrevin, opioid antagonists, remonabant, silver acetatate and nicotine vaccines are under. The current review aims to identify the drugs that have been developed for treatment of tobacco use.
Å°¿öµå
Tobacco, Cessation, Smoking
KMID :
1231220140050020070
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)